Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 6/20 | 0.36 |
| ▸ | CX3CR1 | P49238 | 5/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | DAO | P14920 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.32 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23528831 | 1.00 | MPO (0.38) | MPOCXCR2CX3CR1ADORA1TSHR | |
| SCHEMBL23111758 | 1.00 | MPO (0.38) | MPOCXCR2CX3CR1ADORA1TSHR | |
| SCHEMBL23563198 | 0.78 | MPO (0.36) | MPOCXCR2CX3CR1ADORA1TSHR | |
| SCHEMBL489989 | 0.70 | MPO (0.48) | MPOCXCR2CX3CR1ADORA1PKM | |
| SCHEMBL23111620 | 0.70 | MPO (0.48) | MPOCXCR2CX3CR1ADORA1PKM | |
| SCHEMBL1588262 | 0.70 | MPO (0.48) | MPOCXCR2CX3CR1ADORA1PKM | |
| SCHEMBL1589414 | 0.69 | CX3CR1 (0.61) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL30914153 | 0.69 | CX3CR1 (0.61) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL23528824 | 0.69 | CX3CR1 (0.61) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL21615410 | 0.66 | CX3CR1 (0.60) | MPOCXCR2CX3CR1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230170-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2025-07-17 | — | — | US | disclosed |
| US-12264165-B2 | Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom | KANCERA AB (SE) | 2025-04-01 | — | — | US | disclosed |
| US-20230322807-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322807-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322807-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2023-10-12 | — | — | US | disclosed |
| US-11691988-B2 | Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom | KANCERA AB (SE) | 2023-07-04 | — | — | US | disclosed |
| US-11691988-B2 | Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom | KANCERA AB (SE) | 2023-07-04 | — | — | US | disclosed |
| US-11691988-B2 | Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom | KANCERA AB (SE) | 2023-07-04 | — | — | US | disclosed |
| US-20230068240-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2023-03-02 | — | — | US | disclosed |
| US-20230068240-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2023-03-02 | — | — | US | disclosed |
| US-11542281-B2 | Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom | KANCERA AB (SE) | 2023-01-03 | — | — | US | disclosed |
| US-11542281-B2 | Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom | KANCERA AB (SE) | 2023-01-03 | — | — | US | disclosed |
| US-20210188873-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2021-06-24 | — | — | US | disclosed |
| US-20210188873-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2021-06-24 | — | — | US | disclosed |
| CN-112218853-A | Process for the stereoselective preparation of chiral 2- [ (hetero) aralkylthio ] pyrimidines and products obtainable therefrom | 坎塞拉有限公司 | 2021-01-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322807-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | CYP2S1, CYP2B6, CYP2F1 | MPO 3793/4885CXCR2 1814/4885CX3CR1 3602/4885 |
| US-12264165-B2 | Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom | CYP2B6, CYP2S1, CYP2D6 | MPO 3365/4885CXCR2 430/4885CX3CR1 1795/4885 |
| US-11542281-B2 | Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom | CYP2S1, CYP2B6, CYP2F1 | MPO 3793/4885CXCR2 1814/4885CX3CR1 3602/4885 |
| US-20210188873-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | CYP2S1, CYP2B6, TYMS | MPO 3774/4885CXCR2 1602/4885CX3CR1 3509/4885 |
| US-20230068240-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | CYP2S1, CYP2B6, TYMS | MPO 3774/4885CXCR2 1602/4885CX3CR1 3509/4885 |
| US-20250230170-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | CYP2S1, CYP2B6, CYP2F1 | MPO 3793/4885CXCR2 1814/4885CX3CR1 3602/4885 |
| US-11691988-B2 | Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom | CYP2B6, CYP2S1, CYP2D6 | MPO 3365/4885CXCR2 430/4885CX3CR1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.